DoH advances paediatric cell and gene therapy
The agreement outlines joint fellowships, training programmes and workshops aimed at developing local expertise, positioning Abu Dhabi as a global hub for innovation in life sciences.
Dr Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, said the partnership reflects Abu Dhabi's integrated, patient-centred approach to healthcare. She added, "By combining global expertise with local ambition, we are building a care model that is sustainable, scalable and tailored to the needs of our youngest patients."
Michelle Riley-Brown, President and CEO of Children's National, said the collaboration builds on a long-standing partnership with the UAE, aiming to fast-track the development of cutting-edge therapies and offer new hope to children and families.
The initiative will drive development and delivery of advanced therapies such as Virus-Specific T-cell therapies (VST), with plans to establish Good Manufacturing Practices (GMP) compliant facilities, standardise treatment protocols, and streamline clinical trial systems in Abu Dhabi.
The agreement also covers joint biobanking, data governance improvements and long-term patient care integration. A major component includes Emirati clinician-scientist fellowships and the co-development of specialised training in cellular immunotherapy and trial management.
The partnership will introduce virtual tumour board sessions and hands-on training in cell therapy manufacturing, quality control, and clinical procedures. Complementary workshops will focus on Investigator-Initiated Trials (IITs) and regulatory design, strengthening Abu Dhabi's healthcare workforce.
The agreement follows a high-level Abu Dhabi delegation visit to the United States from 15th to 21st June, 2025, focused on health innovation and investment. Participants included the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, NYU Abu Dhabi, Khalifa University, MBZUAI and startAD.
WAM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
3 hours ago
- Khaleej Times
UAE: Abu Dhabi expat survives cancer, opens green juicery to make ends meet
Ben Smith, a 27-year-old Abu Dhabi resident who grew up in the city, was just 22 when his life was interrupted when doctors diagnosed him with cancer in his appendix, shortly after graduating from university. 'It was the start of my life, really,' he said. 'All my friends were getting jobs, and I was thrown into the hospital.' Over more than a year, Ben underwent treatments, surgeries, and long periods of waiting both in the UAE and the UK. He came out of the experience with no job, no clear plan, not much energy, but a new sense of clarity. Stay up to date with the latest news. Follow KT on WhatsApp Channels. 'When you get cancer, nothing else matters. It puts you face-to-face with what's important, your health, your peace, your community.' With little energy and no clear career path, Ben turned to a skill he had picked up during university while working part-time at Joe & The Juice. He began making juice at home for friends. What started as a casual idea slowly grew into Pink and Greens, a health-conscious juicery that now operates with a strong environmental ethos and nearly zero packaging waste. 'I'm not a businessman,' Ben said. 'I'm more of a family man. I love the environment. I hate plastic. That's just me.' The shop, located at an ADNOC station in Abu Dhabi, has developed organically with the help of a close-knit community. At the core of Ben's business is the Earth Club, a glass bottle return system that encourages customers to bring back used bottles in exchange for a week's worth of free coffee. 'It's become a system that people actually follow,' he said. 'We've created a small loop of reuse, and it works.' Challenges Still, running an eco-conscious store comes with challenges. Paper cups, for example, don't show the colours or layers of the drinks, a key part of the visual appeal. The team is now transitioning to biodegradable cornstarch cups that look like plastic but break down naturally. 'We have to be careful that people don't misunderstand the material,' he said. 'It looks like plastic, but it's made from plants, and it goes back to the earth.' Another challenge is managing the daily pulp generated from juicing fruits and vegetables. While Ben used to compost and deliver the pulp to local farms, he's now actively pursuing new ways to put it to use. 'I don't want it to go to waste,' he said. 'There's real potential in this pulp, and we're looking at how to make sure it stays a part of a sustainable cycle.' 'Everything felt more urgent' Beyond juices, Ben has a wider goal in mind: reviving marine life in the UAE. In collaboration with a government-led initiative, Pink and Greens is planning to launch a bottled water line, where part of each purchase funds the planting of coral reef tiles made from 3D-printed terracotta. These tiles are placed on the seabed to support coral regeneration. 'When someone drinks water from us, they're also helping restore ocean life,' Ben said. 'That's the point, every product has a purpose. We're not just selling drinks. We're trying to make choices that give something back.' Asked whether his interest in sustainability existed before his diagnosis, 'I always respected it. But after cancer, everything felt more urgent,' he said. 'It made me realise this is where I want my life to go, something that makes a real difference.'
Al Etihad
a day ago
- Al Etihad
Abu Dhabi to partner with GEMMABio Therapeutics, advance gene therapies for children with spinal muscular atrophy
5 July 2025 19:52 ABU DHABI (WAM)The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has announced its plans to partner with GEMMABio Therapeutics (GEMMABio), a pioneering global biotechnology company dedicated to advancing global access to gene therapies for rare diseases, in collaboration with M42, a global health champion powered by AI, technology and genomics, and PureHealth, the largest healthcare group in the Middle East. The announcement follows a high-level meeting, during the BIO International Convention 2025 in Boston, between senior leaders from GEMMABio and key stakeholders from Abu Dhabi's health and life sciences ecosystem. Through this strategic partnership, the entities will jointly establish dedicated manufacturing and research centres within Abu Dhabi's academic health institutions, enabling patients from across the MENA region to access cutting-edge clinical trials and, eventually, approved gene collaboration will kick off with a clinical trial evaluating a next-generation gene therapy product in children with spinal muscular atrophy type 1 (SMA1), setting a precedent for expanding access to life-saving therapies Mohamed Alameri, Acting Director of Genome and Biobank Division at the Department of Health – Abu Dhabi, said, 'Our partnership with GEMMABio marks a pivotal step in Abu Dhabi's journey to become a global leader in developing gene therapies for rare diseases leveraging the Emirati Genome Programme. At DoH, we are committed to reshaping innovation, early detection and personalised care by strengthening the Emirate's capacity to develop, test and scale innovative therapeutics. Through these efforts, we are advancing life sciences applications while offering real hope to patients and families across the region and beyond.'The collaboration will unite the shared vision and technology to further strengthen Abu Dhabi's gene therapy R&D ecosystem, and see the emirate serving as a regional hub for GEMMABio's translational and clinical research activities.A best-in-class gene therapy contract development and research manufacturing organisation will be established in Abu Dhabi as a joint venture between M42 and GEMMABio. Additionally, regional access to GEMMABio's commercialised gene products will be coordinated through Abu Dhabi's gene therapy research and treatment by the emirate's state-of-the-art infrastructure, forward-looking policies and the Health, Endurance, Longevity and Medicine (HELM) Life Sciences Cluster, Abu Dhabi is offering streamlined licensing and co-commercialisation processes, alongside co-investment schemes and tax relief for biotech startups. Together, these enablers position Abu Dhabi as a leading global hub for life sciences Jim Wilson, Founder, President, and CEO of GEMMABio, said, 'This is a transformational partnership—one that will play a pivotal role in unlocking global access to life-saving treatments for patients with rare diseases. The stakeholders in Abu Dhabi are building a globally recognised gene therapy ecosystem whose impact on the future of life sciences will be both profound and far-reaching. Together, we are aligning scientific innovation with bold ambition to accelerate progress where it's needed most.'Dimitris Moulavasilis, Group Chief Executive Officer of M42, said, 'This partnership helps Abu Dhabi usher in another frontier in the future of health. With our integrated AI- and data-led ecosystem and advancements in precision, prevention, and prediction, this collaboration extends the impact of the Emirati Genome Programme into gene therapeutics targeting rare diseases."M42 is focused on developing genomic insights, fighting against rare diseases and saving lives. Our partnership with the Department of Health – Abu Dhabi and GEMMABio will accelerate this effort, ensuring people in the UAE and beyond get the gene therapies they need for longer, healthier lives.'This strategic partnership reinforces Abu Dhabi's recent strides in rare disease gene therapies and precision medicine. The emirate has significantly expanded its genomics capabilities through the Emirati Genome Programme, with over 800,000 genome samples sequenced, marking one of the world's most advanced national genomic Dhabi continues to pioneer the administration of cutting-edge gene therapies, expanding access to life-saving treatments that were previously unavailable in the region. With sustained investment in research, talent, and infrastructure, the emirate is reinforcing its position as a regional leader in life sciences and medical Saif Al Qubaisi, Group Chief Operating Officer of PureHealth, said, 'This collaboration is a powerful reflection of Abu Dhabi's growing influence as a global centre for health innovation. By joining forces with GEMMABio and our strategic partners, we are not only expanding access to advanced gene therapies, but also reinforcing the Emirate's long-term commitment to solving some of the world's most complex health challenges. PureHealth is proud to contribute through its integrated research capabilities and commitment to clinical excellence, aligned with the Department of Health's vision to deliver life-changing outcomes for patients across the region and beyond.'Led by DoH, a high-level delegation embarked on a strategic mission to the US from June 15 to 21, 2025. This visit focused on knowledge exchange, investment opportunities, and the signing of new agreements aimed at accelerating the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation included key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI), and startAD.
Gulf Today
a day ago
- Gulf Today
DoH advances paediatric cell and gene therapy
The Department of Health - Abu Dhabi (DoH) has signed a strategic Memorandum of Understanding with Children's National Hospital in Washington, D.C., to establish the Abu Dhabi - Children's National Hospital Cell and Gene Therapy Clinical Excellence Programme. The partnership marks a major step in advancing access to paediatric cell and gene therapies across the UAE. The agreement outlines joint fellowships, training programmes and workshops aimed at developing local expertise, positioning Abu Dhabi as a global hub for innovation in life sciences. Dr Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, said the partnership reflects Abu Dhabi's integrated, patient-centred approach to healthcare. She added, "By combining global expertise with local ambition, we are building a care model that is sustainable, scalable and tailored to the needs of our youngest patients." Michelle Riley-Brown, President and CEO of Children's National, said the collaboration builds on a long-standing partnership with the UAE, aiming to fast-track the development of cutting-edge therapies and offer new hope to children and families. The initiative will drive development and delivery of advanced therapies such as Virus-Specific T-cell therapies (VST), with plans to establish Good Manufacturing Practices (GMP) compliant facilities, standardise treatment protocols, and streamline clinical trial systems in Abu Dhabi. The agreement also covers joint biobanking, data governance improvements and long-term patient care integration. A major component includes Emirati clinician-scientist fellowships and the co-development of specialised training in cellular immunotherapy and trial management. The partnership will introduce virtual tumour board sessions and hands-on training in cell therapy manufacturing, quality control, and clinical procedures. Complementary workshops will focus on Investigator-Initiated Trials (IITs) and regulatory design, strengthening Abu Dhabi's healthcare workforce. The agreement follows a high-level Abu Dhabi delegation visit to the United States from 15th to 21st June, 2025, focused on health innovation and investment. Participants included the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, NYU Abu Dhabi, Khalifa University, MBZUAI and startAD. WAM
